BlackRock, Inc. Reduces Stake in Stoke Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a reduction in its ownership of Stoke Therapeutics, Inc. common stock. As of September 30, 2025, BlackRock owns 3,732,540 shares, representing a 6.8% ownership stake. This marks a decrease of 310,533 shares (7.68%) from its previous filing. The filing indicates that BlackRock holds sole voting power over 3,666,122 shares and sole dispositive power over all 3,732,540 shares. The filing also notes that various persons have the right to receive dividends or proceeds from the sale of the shares, but no single person's interest exceeds 5% of the total outstanding shares. The amendment was signed by Spencer Fleming, Managing Director, on October 17, 2025.